OnDemand WTP Pricing Research

Teva, Mylan and Heritage are stonewalling pricing probe, US lawmakers say | S&P Global Market Intelligence

U.S. House Oversight and Reform Committee Chairman Elijah Cummings, D-Md., and Sen. Bernie Sanders, I-Vt., a presidential candidate, reignited their probe into three generic-drug manufacturers’ pricing practices and accused the companies of stonewalling the lawmakers’ 2014 congressional investigation.

“Obstructing or evading a congressional investigation, including withholding or concealing information, is a violation of federal law,” Cummings and Sanders said in Aug. 13 letters to Teva Pharmaceutical Industries Ltd., Mylan NV and Heritage Pharmaceuticals Inc.

Not only did the companies’ “apparent obstruction” undermine the investigation, “but it may have caused further harm to patients and healthcare providers by delaying the discovery of evidence about the companies’ price-fixing,” Cummings and Sanders wrote.

Read complete article here:

Teva, Mylan and Heritage are stonewalling pricing probe, US lawmakers say | S&P Global Market Intelligence.

Post a Comment

WP-SpamFree by Pole Position Marketing